How healthy and JAK2‑mutant blood stem cells compete in myeloproliferative neoplasms
Cell Competition in Myeloproliferative Neoplasms
This work looks at whether healthy blood stem cells can keep JAK2‑mutant cells from taking over in people with myeloproliferative neoplasms.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University New York Stony Brook NIH-funded |
| Lab location | 1 site (Stony Brook, United States) |
| Project ID | NIH-11131232 on NIH RePORTER |
What this research studies
Researchers grow healthy and JAK2V617F‑mutant blood stem/progenitor cells together in lab dishes and follow which cells expand. They transplant competing cells into animal models to observe how mutant and wild‑type cells behave in a living bone marrow environment. The team measures signals such as the Notch ligand Dlk1 and examines how a mutant marrow environment influences competition. The goal is to find signals or conditions that help healthy cells outcompete mutant clones and prevent progression to frank leukemia.
Who could benefit from this research
Good fit: Ideal candidates for related clinical efforts would be people with myeloproliferative neoplasms (for example, polycythemia vera, essential thrombocythemia, or myelofibrosis) who carry the JAK2V617F mutation or have detectable clonal blood cells.
Not a fit: People whose disease is driven by non‑JAK2 mutations or who already have transformed acute leukemia may not benefit from strategies focused on JAK2‑driven cell competition.
Why it matters
Potential benefit: If successful, this could point to treatments that boost healthy stem cells or change the marrow environment to reduce mutant clone expansion and lower the risk of leukemia.
How similar studies have performed: Laboratory and animal studies have shown that healthy cells can sometimes suppress mutant clones, but translating these findings into effective patient treatments remains largely unproven.
Where this research is happening
Stony Brook, United States
- State University New York Stony Brook — Stony Brook, United States (Active)
Researchers
- Principal investigator: Zhan, Huichun — State University New York Stony Brook
- Study coordinator: Zhan, Huichun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.